| Autor: |
Zhang ER; Faculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada., Ghezelbash S; Faculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.; Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.; Lady Davis Institute for Medical Research, Montreal, QC H3T 1E2, Canada., Xie P; Faculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.; Division of Dermatology, Department of Medicine, McGill University, Montreal, QC H3T 1E2, Canada., Fotovati M; Faculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada., Litvinov IV; Faculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.; Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.; Division of Dermatology, Department of Medicine, McGill University, Montreal, QC H3T 1E2, Canada., Lefrançois P; Faculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.; Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.; Lady Davis Institute for Medical Research, Montreal, QC H3T 1E2, Canada.; Division of Dermatology, Department of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.; Division of Dermatology, Department of Medicine, Jewish General Hospital, Montreal, QC H3T 1E2, Canada. |
| Abstrakt: |
Basal cell carcinoma (BCC) is the most common form of skin cancer, contributing to nearly a third of new cancer cases in Western countries. Most BCCs are considered low risk "routine" lesions that can either be excised through surgery or treated with chemotherapeutic agents. However, around 1-2% of BCC cases are locally aggressive, present a high risk of metastasis, and often develop chemoresistance, termed advanced BCC. There currently exists no animal model or cell line that can recapitulate advanced BCC, let alone intermediate-risk and high-risk early BCC. We previously found that aggressive BCC tumours presented a Th2 cytokine inflammation profile, mesenchymal stem cell properties, and macrophage-induced tumoral inflammation. In this study, we aimed to identify potential BCC "relatives" among solid-organ malignancies who present similar immune cell proportions in their microenvironment compositions. Using immune cell type deconvolution by CIBERSORTx, and cell type enrichment by xCell, we determined three cancers with the most similar tumour microenvironments as compared to BCC. Specifically, chromophobe renal cell carcinoma, sarcoma, and skin cutaneous melanoma presented significance in multiple cell types, namely in CD4+ T lymphocytes, gammadelta T lymphocytes, and NK cell populations. Consequently, further literature analysis was conducted to understand similarities between BCC and its "relatives", as well as investigating novel treatment targets. By identifying cancers most like BCC, we hope to propose prospective druggable pathways, as well as to gain insight on developing a reliable animal or cell line model to represent advanced BCC. |
